The Tyrosine Phosphatase hPTPRβ Controls the Early Signals and Dopaminergic Cells Viability via the P2X7 Receptor

Francisco Llavero Bernal 1,2,* 1, Miriam Luque Montoro 1, Alazne Arrazola Sastre 1,3, Hadriano M. Lacerda 4 and José Luis Zugaza 1,3,5,6,*

1 Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU, 48940 Leioa, Spain; miriamluquem@gmail.com (M.L.M.); alazne.arrazola@ehu.eus (A.A.S.)
2 Research Institute of the Hospital 12 de Octubre (i + 12), 28041 Madrid, Spain
3 Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain
4 Three R Labs, Science Park of the UPV/EHU, 48940 Leioa, Spain; hadrilac@gmail.com
5 IKERBASQUE, Basque Foundation for Science, Plaza Euskadi, 48009 Bilbao, Spain
6 *Correspondence: Francisco.llavero@ehu.eus (F.L.B.); joseluis.zugaza@ehu.es (J.L.Z.)

Abstract: ATP, one of the signaling molecules most commonly secreted in the nervous system and capable of stimulating multiple pathways, binds to the ionotropic purinergic receptors, in particular, the P2X7 receptor (P2X7-R) and stimulates neuronal cell death. Given this effect of purinergic receptors on the viability of dopaminergic neurons model cells and that Ras GTPases control Erk1/2-regulated mitogen-activated cell proliferation and survival, we have investigated the role of the small GTPases of the Ras superfamily, together with their regulatory and effector molecules as the potential molecular intermediates in the P2X7-R-regulated cell death of SN4741 dopaminergic neurons model cells. Here, we demonstrate that the neuronal response to purinergic stimulation involves the Calmodulin/RasGRF1 activation of the small GTPase Ras and Erk1/2. We also demonstrate that tyrosine phosphatase PTPRβ and other tyrosine phosphatases regulate the small GTPase activation pathway and neuronal viability. Our work expands the knowledge on the intracellular responses of dopaminergic cells by identifying new participating molecules and signaling pathways. In this sense, the study of the molecular circuitry of these neurons is key to understanding the functional effects of ATP, as well as considering the importance of these cells in Parkinson’s Disease.

Keywords: P2X7 receptor; Ras GTPase; Erk1/2; hPTPRβ; dopaminergic neurons; Parkinson’s

1. Introduction

Purines may initiate signal transduction pathways in different cell lineages and tissues. These signaling networks are controlled by specific cell membrane receptors known as purinergic or purinoceptors [1]. They are classified into two types, metabotropic or P1 receptors and ionotropic or P2 receptors. Whereas P1 receptors bind heterotrimeric G proteins, ionotropic or P2 receptors can either bind heterotrimeric G proteins (P2Y) or form ion channels (P2X), exclusively activated by ATP, with selective permeability to Ca2+, Na+, and K+ [2]. The P2X receptors are expressed primarily in excitable cells, and seven subtypes (P2X1–7) [3] have been cloned. Amongst them, P2X7 is a purinergic ATP-binding receptor expressed at high levels in the central nervous system (CNS) [4–7]; therefore, it attracts the most attention [8].

The P2X receptor (P2X7-R) is considered key in promoting an inflammatory response in pathological processes, such as neuroinflammation and neurodegeneration [6,9–11]. In this regard, there is evidence that the P2X7-R pathway causes neuronal damage, leading to progressive neurodegeneration [11]. In fact, it has been reported that P2X7-R antagonists can attenuate neuronal dysfunction and damage in a mouse model of Parkinson’s disease [12]. Additionally, selective inhibition of P2X7-R also markedly protected dopaminergic (DA) neurons of the substantia nigra (SN) in rats [13–15].

---

Article

The Tyrosine Phosphatase hPTPRβ Controls the Early Signals and Dopaminergic Cells Viability via the P2X7 Receptor

Francisco Llavero Bernal 1,2,* 1, Miriam Luque Montoro 1, Alazne Arrazola Sastre 1,3, Hadriano M. Lacerda 4 and José Luis Zugaza 1,3,5,6,*

1 Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU, 48940 Leioa, Spain; miriamluquem@gmail.com (M.L.M.); alazne.arrazola@ehu.eus (A.A.S.)
2 Research Institute of the Hospital 12 de Octubre (i + 12), 28041 Madrid, Spain
3 Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain
4 Three R Labs, Science Park of the UPV/EHU, 48940 Leioa, Spain; hadrilac@gmail.com
5 IKERBASQUE, Basque Foundation for Science, Plaza Euskadi, 48009 Bilbao, Spain
6 *Correspondence: Francisco.llavero@ehu.eus (F.L.B.); joseluis.zugaza@ehu.es (J.L.Z.)

Abstract: ATP, one of the signaling molecules most commonly secreted in the nervous system and capable of stimulating multiple pathways, binds to the ionotropic purinergic receptors, in particular, the P2X7 receptor (P2X7-R) and stimulates neuronal cell death. Given this effect of purinergic receptors on the viability of dopaminergic neurons model cells and that Ras GTPases control Erk1/2-regulated mitogen-activated cell proliferation and survival, we have investigated the role of the small GTPases of the Ras superfamily, together with their regulatory and effector molecules as the potential molecular intermediates in the P2X7-R-regulated cell death of SN4741 dopaminergic neurons model cells. Here, we demonstrate that the neuronal response to purinergic stimulation involves the Calmodulin/RasGRF1 activation of the small GTPase Ras and Erk1/2. We also demonstrate that tyrosine phosphatase PTPRβ and other tyrosine phosphatases regulate the small GTPase activation pathway and neuronal viability. Our work expands the knowledge on the intracellular responses of dopaminergic cells by identifying new participating molecules and signaling pathways. In this sense, the study of the molecular circuitry of these neurons is key to understanding the functional effects of ATP, as well as considering the importance of these cells in Parkinson’s Disease.

Keywords: P2X7 receptor; Ras GTPase; Erk1/2; hPTPRβ; dopaminergic neurons; Parkinson’s

1. Introduction

Purines may initiate signal transduction pathways in different cell lineages and tissues. These signaling networks are controlled by specific cell membrane receptors known as purinergic or purinoceptors [1]. They are classified into two types, metabotropic or P1 receptors and ionotropic or P2 receptors. Whereas P1 receptors bind heterotrimeric G proteins, ionotropic or P2 receptors can either bind heterotrimeric G proteins (P2Y) or form ion channels (P2X), exclusively activated by ATP, with selective permeability to Ca2+, Na+, and K+ [2]. The P2X receptors are expressed primarily in excitable cells, and seven subtypes (P2X1–7) [3] have been cloned. Amongst them, P2X7 is a purinergic ATP-binding receptor expressed at high levels in the central nervous system (CNS) [4–7]; therefore, it attracts the most attention [8].

The P2X receptor (P2X7-R) is considered key in promoting an inflammatory response in pathological processes, such as neuroinflammation and neurodegeneration [6,9–11]. In this regard, there is evidence that the P2X7-R pathway causes neuronal damage, leading to progressive neurodegeneration [11]. In fact, it has been reported that P2X7-R antagonists can attenuate neuronal dysfunction and damage in a mouse model of Parkinson’s disease [12]. Additionally, selective inhibition of P2X7-R also markedly protected dopaminergic (DA) neurons of the substantia nigra (SN) in rats [13–15].

---

Citation: Bernal, F.L.; Luque Montoro, M.; Arrazola Sastre, A.; Lacerda, H.M.; Zugaza, J.L. The Tyrosine Phosphatase hPTPRβ Controls the Early Signals and Dopaminergic Cells Viability via the P2X7 Receptor. Int. J. Mol. Sci. 2021, 22, 12936. https://doi.org/10.3390/ijms222312936

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
ATP activation of the P2X7R stimulates multiple signaling pathways via its interaction with a complex of eleven different proteins, such as laminin α3, integrin β2, the receptor tyrosine phosphatase β (PTPRβ), α-actinin 4, β-actin, supervilin, heat shock proteins Hsp90, Hsc71, and Hsp70, phosphatidylinositol kinase 4 (PI4K), and membrane-associated protein guanylate kinase P55 (MaGuK) [16]. Two of the eleven proteins, PTPRβ and Hsp90, were proposed to modulate P2X7 receptor function [16,17]. These interactions allow the P2X7R to act as a transducer between the extracellular medium and the intracellular signaling pathways to modulate ion fluxes (Ca2+ and Na+ influx, K+ efflux), NADPH oxidase complex and reactive oxygen species (ROS) generation, and activation of phospholipase D, MAPKs (Erk1/2), p38, JNKs, and several caspsases [18].

Ras GTPases control Erk1/2 serine/threonine kinases that regulate mitogen-activated cell proliferation connecting cellular responses to extracellular signals and playing an essential role on the modulation of a wide range of cellular processes both in health and diseases, such as cancer, and cardiopathies, including the neuronal responses [19] in neurocognitive and neurodegenerative diseases, such as Parkinson’s Disease [20–23]. The Ras GTPases function as molecular switches that cycle between an inactive GDP-bound and an active GTP-bound state. The transition between the inactive to the active state is regulated by three main molecules: guanine nucleotide exchange factors (GEF), GTPase activating proteins (GAP), and GDP dissociation inhibitors (GDI) [24].

Here, using SN4741 cells, a neuronal cell line derived from murine Substance Ni-gra [25], we showed that P2X7 receptor stimulation leads to Ras and Erk1/2 activation. By combining pharmacological and genetic approaches, we identified the tandem Ca2+-Calmodulin/Ras GRF1 activation as a bridge between the P2X7 receptor and the Ras/Erk1/2 pathway. We also show that PTPRβ tyrosine phosphatase controls not only the P2X7 receptor-mediated Ras activation, but it also controls dopaminergic cells viability. Overall, these results reveal unexpected crosstalk between the P2X7 receptor and the small GTPase Ras to modulate cell viability through PTPRβ. Interestingly, we demonstrated that dopaminergic neurons control of PTPRβ and Ras can maintain their viability. This being a central issue in palliating Parkinson’s Disease neurodegeneration.

2. Results
2.1. 0.5 mM ATP Mediates Erk1/2 Phosphorylation via the P2X7 Receptor without Affecting Cell Viability

The P2X7 receptor activation has been widely associated to the cell death program in different cell types [26–29]. In Jun et al., it was reported that the P2X7 receptor stimulated with 3 mM ATP mediated the SN4741 cells necrotic death [30]. To examine whether SN4741 cellular viability depends on the ATP concentration, SN4741 cells were treated, or not, with different concentrations of ATP for 5 min, and an MTT assay was used to measure the cell’s viability. As shown in Figure 1A, SN4741 cellular viability was not affected by either 0.5 or 1 mM ATP. However, 3 mM ATP significantly reduced cellular viability (Figure 1A). This result allowed us to establish 0.5 mM ATP as the working concentration to investigate the P2X7 receptor intracellular signaling.

| Drug Name | Activity | Treatment | Concentration |
|-----------|----------|-----------|---------------|
| ATP       | Agonist of P2X receptors | 5 min | 500 µM |
| BzATP     | Specific agonist of P2X7 receptor | 10 min | 100 µM |
| A-740003  | Specific antagonist of P2X7 receptor | 30 min | 100 nM |
| GF109203X hydrochloride | PKC inhibitor | 1 h | 1 µM |
| Na3VO4    | Tyrosine phosphatase inhibitor | 20 min | 1 mM |
Figure 1. The ATP-stimulated P2X<sub>7</sub> receptor controls cellular viability and Erk1/2 phosphorylation in SN4741 cells. (A) SN4741 cells were serum-starved overnight and stimulated, or not, with different concentration of ATP for 5 min, and the cellular viability was measured by MTT assay. The values are represented as the percentage on control (untreated cells) and show the mean of five independent experiments ± SEM. SN4741 overnight-serum-starved cells were (B) stimulated, or not, with different concentrations of ATP for 5 min, (C) 0.5 mM ATP for 5 min or 100 µM BzATP for 10 min, (D) pre-treated with or without 100 nM A740003 (Table 1) for 1 h and, subsequently, stimulated, or not, with 0.5 mM ATP for 5 min, and lysed. Cell extracts were analyzed by Western blot using an anti-phospho-Erk1/2 antibody. The Erk1/2 amounts present in the samples analyzed were examined with an anti-Erk<sub>1</sub>/2 antibody. The β-Actin amounts present in the samples analyzed in lower panel were examined with an anti-β-Actin antibody. Results show the mean of seven independent experiments ± SEM. Statistical analysis shows a significant difference (** p < 0.01, *** p < 0.001 and ### p < 0.001).
Next, we investigated the relationship between purinergic receptors and Erk activation, which seems to play an important role in the regulation of both physiological and pathological cellular responses [31]. Thus, SN4741 cells were treated with different concentrations of ATP for 5 min. This was followed by SDS-PAGE separation of protein lysates and Western blot analysis of Erk1/2 phosphorylation. ATP of 0.5 mM is the minimum concentration capable of inducing maximum Erk1/2 phosphorylation (Figure 1B (second lane (0.47) compared with first lane (0.18)). It must also be taken into account that this concentration of ATP is not toxic for SN4741 cells, as shown in Figure 1A.

To demonstrate that P2X<sub>7</sub> receptor was involved in Erk1/2 phosphorylation in SN4741 cells, the most specific P2X<sub>7</sub> receptor agonist, BzATP (2,3-O-(4-benzoyl benzoyl)-ATP), was used [32]. Thus, SN4741 cells were treated, or not, with 0.5 mM ATP or with 100 µM BzATP for 5 min and lysed. This was followed by SDS-PAGE separation of protein lysates and Western blot analysis of Erk1/2 phosphorylation. The results show that BzATP stimulated Erk1/2 phosphorylation equally well as ATP (Figure 1C, upper panel, lanes 2 (2.9) and 3 (2.7) and histogram bars 2 and 3 (2.9 and 2.7, respectively)). In addition, we used A740003, a highly selective P2X<sub>7</sub> receptor antagonist compared to other P2 receptors [33]. SN4741 cells were pre-treated, or not, with 100 nM A-740003 (Table 1) for 1 h and treated, or not, with 0.5 mM ATP for 5 min and lysed. This was followed by SDS-PAGE separation of protein lysates and Western blot analysis of Erk1/2 phosphorylation. As shown in Figure 1D, the antagonist not only did not block but enhanced Erk phosphorylation (upper panel lane and bar 4 (6.74) compared to lane and histogram bar 2 (2.9)). These results suggest that P2X<sub>7</sub> receptor activation does not mediate ATP-stimulated Erk phosphorylation.

2.2. P2X<sub>7</sub> Receptor Specific Control of Ras Activation in SN4741 Cells

The Ras GTPase-mediated canonical activation of Erk prompted us to find out what is the state of Ras in conditions similar to those described for Erk1/2. Thereby, SN4741 cells were treated, or not treated, with 0.5 mM ATP or with 100 µM BzATP for 5 min. Cells were lysed, and the endogenous active Ras was measured by the pulldown assay, as described in Materials and Methods section. As shown in Figure 2A, ATP stimulated the activation of Ras GTPase as strongly as BzATP (Table 1), the P2X<sub>7</sub> receptor most specific agonist (upper panel and histogram lane 2 (2.91) and 3 (2.73)). To verify that the P2X<sub>7</sub> receptor was specifically involved in Ras activation, SN4741 cells were previously treated, or not, with 100 µM A-740003 (Table 1) for 1 h and treated, or not, with 0.5 mM ATP for 5 min. SN4741 cells were lysed, and the endogenous active Ras was measured by the pulldown assay. Results show that ATP stimulated Ras activation, as expected, but A-740003, a P2X<sub>7</sub> receptor antagonist, strongly reduced the ATP-stimulated Ras activation (Figure 2B (upper panel lane and bar 4 (1.9) compared to lane and histogram bar 2 (3.4)). This finding suggests that, unlike Erk activation, P2X<sub>7</sub> receptor could mediate Ras activation, at least partially.

Going further, we examined whether other GTPases of the Ras family, such as Rap1, or of the Rho family, such as RhoA, Rac1, and Cdc42, could be activated under the same conditions as Ras in SN4741 cells. To this end, SN4741 cells were treated, or not, with 0.5 mM ATP for 5 min, then cells were lysed, and the endogenous active Rap1, RhoA, Rac1, and Cdc42 were captured with the pull-down assay and measured, as described in the Materials and Methods section. Except for Ras, none of the other GTPases was activated after ATP stimulation of SN4741 cells (Figure 2C).
Figure 2. The P2X<sub>7</sub> receptor-mediated specific Ras activation in SN4741 cells. The SN4741 cells were serum-starved overnight and treated, or not, with 0.5 mM ATP for 5 min and lysed. (A) Cell lysates were used to measure Ras, Rap1, RhoA, Rac1, and Cdc42 activation by the affinity precipitation assay. The precipitated active GTPases (binds to GTP) and the total GTPases expression levels were analyzed by Western blotting using a specific antibody. The precipitated active Ras (Ras-GTP) and the total Ras expression level were analyzed by Western blotting using an anti-Ras antibody. The β-Actin amounts present in the samples analyzed in lower panel were examined with an anti-β-Actin antibody. Immunoblots are representative of seven independent experiments. (B) Serum-starved SN4741 cells were treated, or not, with 0.5 mM ATP for 5 min, and 100 µM BzATP for 10 min, or (C) previously treated with or without 100 nM A740003 for 1 h before a 5-min stimulation, or not, with 0.5 mM ATP and lysed. Cell lysates were used to measure Ras activation by the affinity precipitation assay. The precipitated active Ras (Ras-GTP) and the total Ras expression level were analyzed by Western blotting using an anti-Ras antibody. The β-Actin amounts present in the samples analyzed in lower panel were examined with an anti-β-Actin antibody. Immunoblots are representative of five independent experiments. Each histogram bar includes the values of five different samples. All values are expressed as fold change. The differences between treatments were p < 0.001 in all cases (***)

2.3. P2X<sub>7</sub> Receptor-Specific Control of Ras Activation Is via the Ca<sup>2+</sup>-Calmodulin/RasGRF1 Signaling Pathway

Next, we aimed to identify the guanine nucleotide exchange factor (GEF) that preferentially activates Ras in our cellular system. Assuming that RasGRF1 is one of the GEFs that mediates Ras activation, and it is highly expressed in the central nervous system [34], we selected the easily transfected HEK 293T cell system to investigate P2X<sub>7</sub> receptor and RasGRF1 functions since these cells do not express either the P2X<sub>7</sub> receptor or RasGRF1 [35,36].

HEK 293T cells were co-transfected with the pCEFL-HA-P2X<sub>7</sub> receptor and pEGFP-RasGRF1(wt) or pEGFP-RasGRF1<sup>R214Q,R219Q,K223Q</sup> (pEGFP-RasGRF1 mut-IQ), or pCEFL-HA-P2X<sub>7</sub> with pcDNA3YFP-CaM mut or pCEFL-HA-P2X<sub>7</sub> receptor with pcDNA3CaM mut and pEGFP-RasGRF1 (wt), as indicated in Figure 3. After 48 h, cells were treated, or not, with 0.5 mM ATP for 5 min and lysed, and endogenous active Ras was captured with the pull-down assay and measured, as described in the Materials and Methods. As expected, ATP did not induce Ras activation either in non- or P2X<sub>7</sub> receptor transfected cells (Figure 3, first panel, lanes 2 and 4, and histogram bars 2 and 4 (both 1.47)); however, the P2X<sub>7</sub> receptor/ RasGRF1(wt) co-expression rendered possible a robust increase in Ras activation in both ATP-treated and untreated cells (Figure 3, first panel, lanes and bars 5 (4) and 6 (4.32) compared to lanes and bars 1, 2, 3, and 4 (0.98–1.47)). We hypothesize that the Ras activation in untreated cells was due to the overexpression of RasGRF1. In general, it is well accepted that GEF overexpression per se is enough to mediate the small GTPase activation. Furthermore, the IQ domain RasGRF1 mutant (RasGRF1 mut-IQ) responsible for the binding to Calmodulin was unable to mediate Ras activation, even in the presence
of P2X7 receptor (Figure 3, first panel, lanes and bars 7 (1.7) and 8 (1.64) compared to lanes and bars 5 (4) and 6 (4.32)). This finding suggested that the calmodulin-binding domain of RasGRF1 was necessary for the correct signal transduction. To verify this result, the P2X7 receptor and RasGRF1(wt) were co-transfected, together with a calmodulin mutant form (CaM mut), unable to bind calcium. As shown in Figure 3, CaM mut efficiently blocked Ras activation both in treated and untreated cells (lanes and bars 11 (2.06) and 12 (1.86) compare to lanes and bars 5 (4) and 6 (4.32)). Altogether, these results suggest that the P2X7 receptor recruits in tandem Ca2+-Calmodulin/RasGRF1 to activate Ras.

Figure 3. The P2X7 receptor requires CaM/RasGRF1 pathway to activate Ras in HEK 293 T cells. The HEK 293 T cells were transfected with empty vector (mock control), pCELF-HA-P2X7 receptor, or co-transfected with the P2X7 receptor, together with pEGFP-RasGRF1wt, pEGFP-RasGRF1mutIQ, or pcDNA3YFP-CaM mut, or with a combination of the pEGFP-RasGRF1wt and pcDNA3YFP-CaM mut. Forty-eight hours post-transfection, cells were treated, or not, with 0.5 mM ATP for 5 min and lysed. Cell lysates were used to measure Ras activation by the affinity precipitation assay. The precipitated active Ras (Ras-GTP), total Ras, P2X7 receptor, RasGRF1wt, RasGRF1mutIQ, and CaM mut expression levels were analyzed by Western blotting using specific antibodies. The β-Actin amounts present in the samples analyzed in lower panel were examined with an anti-β-Actin antibody. Immunoblots are representative of five independent experiments. Each histogram bar includes the values of seven different samples. All values are expressed in fold change. The differences between treatments were p < 0.001 in all cases (***)
2.4. Tyrosine Phosphatases Regulate Ras/Erk Activation and Control SN4741 Cell Viability via the P2X7 Receptor

The reported basal phosphatase-activity mediating the P2X7 receptor dephosphorylation [16] prompted us to investigate whether tyrosine phosphatase activity is involved in controlling the P2X7 receptor signaling in SN4741 cells. For this purpose, SN4741 cells were previously treated, or not, with 1 mM of the tyrosine phosphatase inhibitor sodium orthovanadate (Na3VO4) (Table 1) for 20 min and treated, or not, with 0.5 mM ATP for 5 min and lysed. Endogenous active Ras was captured with the pull-down assay and measured, as described in the Materials and Methods. As expected, ATP induced strong Ras activation, while Na3VO4 did not affect it (Figure 4A upper panel lanes 2 (3.38), 4 (2.94) and bars 2, 4)). Regarding Erk1/2, cell protein lysates were separated by SDS-PAGE, and Erk1/2 phosphorylation was analyzed by Western blot. As shown in Figure 4B, ATP induced robust Erk1/2 phosphorylation, and Na3VO4 did not affect it (upper panel lanes 2, 4 and bars 2, 4 (2.65 and 3.38, respectively)). However, in the absence of ATP stimulus, Na3VO4 significantly enhanced Erk1/2 phosphorylation (Figure 4B, upper panel lane 3, bar 3 (1.92)).

![Figure 4](image_url)

**Figure 4.** The tyrosine phosphatases mediate Ras/Erk1/2 activation and control SN4741 cells viability. SN4741 cells were serum-starved overnight, and cells were previously treated, or not, with 1 mM Na3VO4 for 20 min and subsequently stimulated, or not, with 0.5 mM ATP for 5 min and lysed. Cell lysates were used to measure (A) Ras activation by the affinity precipitation assay and (B) ERK1/2 phosphorylation in total extracts. The precipitated active Ras (Ras-GTP), p44/42 phosphorylation, total Ras, Erk 1/2, and β-Actin expression levels were analyzed by Western blotting using specific antibodies. Immunoblots are representative of four independent experiments. Each histogram bar includes the values of four different samples. All values are expressed in fold change. The differences between treatments were p < 0.001 in all cases (***) (Mann–Whitney test). (C) SN4741 cells were serum-starved overnight and were treated, or not, with 1 mM Na3VO4 for 20 min and subsequently stimulated, or not, with 0.5 mM ATP for 5 min, and cellular viability was measured by the MTT assay. All values are represented as the percentage over control (untreated) cells and show the mean of seven independent experiments ± SEM. Statistical analysis shows a significant difference (** p < 0.01 and *** p < 0.001).

Furthermore, we examined the tyrosine phosphatases potential role in SN4741 cell viability. Cells were previously treated, or not, with 1 mM Na3VO4 for 20 min and treated, or not, with 0.5 mM ATP for 5 min, and the MTT assay measured cell viability. As shown in Figure 4C, ATP did not alter the cell viability, while Na3VO4 strongly increased cell viability both in the absence and in the presence of ATP, i.e., between 20 to 30% higher than control (Figure 4C, bars 3 and 4). All these findings suggest that tyrosine phosphatases regulate RasGTPase/Erk activation and control cell viability in the P2X7 receptor-dependent manner.
2.5. PTPRβ Regulates Ras/Erk Activation and Controls SN4741 Cell Viability via the P2X7 Receptor

Our results, together with the well-described molecular binding between the P2X7 receptor and the tyrosine phosphatase beta (PTPRβ) [16], prompted us to examine a putative role of PTPRβ in the P2X7 receptor signaling leading to Ras/Erk activation and SN4741 cell viability control. We approached the question genetically by knocking down PTPRβ in SN4741 cells. To this end, SN4741 cells were transfected with esiRNA mouse PTPRβ or esiRNA targeting EGFP as a negative control. Twenty-four hours post-transfection, Ras activation was determined in both SN4741 cells stimulated with ATP for 5 min and unstimulated. As shown in Figure 5A, ATP stimulated robust Ras activation in egfp(esiRNA)-transfected SN4741 cells. Non-stimulated ptprb-knockdown (ptprβ(esiRNA)) cells exhibited increased Ras active configuration (upper panel, lane and bar 4 (3.42) compared to lane and bar 2 (2.65)). When we measured the Erk phosphorylation state, under the same conditions as Ras, we obtained the same results; the absence of ptprb expression enhanced Erk phosphorylation (Figure 5B, upper panel lane and bar 4 (3.7) compared to lane and bar 2 (2.57)).

**Figure 5.** PTPRβ controls cellular viability and Ras and Erk1/2 activation in SN4741 cells. SN4741 cells were transfected with esiPTPRβ or esiEGFP as control. Twenty-four hours post-transfection, SN4741 cells were serum-starved overnight. Then, cells were treated, or not, with 0.5 mM ATP for 5 min and lysed. The cell lysates were used to measure Ras activation by the affinity precipitation assay and Erk1/2 phosphorylation in total extracts. (A) The precipitated active Ras (Ras-GTP), (B) p44/42 phosphorylation, and the total Ras, Erk1/2 and β-Actin expression levels were analyzed by Western blotting using specific antibodies. Immunoblots are representative of four independent experiments. Each histogram bar includes values of three different samples. All values are expressed in fold change. Differences between treatments were p < 0.01 (**) or p < 0.001 (***) (Mann–Whitney test). (C) SN4741 cells were transfected with esiPTPRβ or esiEGFP as control. Twenty-four hours post-transfection, SN4741 cells were serum-starved overnight and stimulated, or not, with different 0.5 mM ATP for 5 min, and cellular viability was measured by the MTT assay. Values are presented as the percentage of control (untreated) cells, and they are representative of five experiments. Cells were serum-starved (1% FBS) overnight and previously treated, or not, with 1 mM Na3VO4 for 20 min and subsequently stimulated, or not, with 0.5 mM ATP for 5 min, and cellular viability was measured by the MTT assay. Values are presented as the percentage over control (untreated) cells and represent the mean of five independent experiments ± SEM. Statistical analysis shows a significant difference (**) p < 0.01 and (***) p < 0.001).

Last, we investigated whether the absence of PTPRβ expression modified SN4741 cells viability. SN4741 cells were transfected with esiRNA mouse PTPRβ or esiRNA targeting EGFP as a negative control. Twenty-four hours post-transfection, cell viability was determined in both SN4741 cells stimulated with ATP for 5 min and unstimulated by MTT assay. As shown in Figure 5C, ATP did not modify cell viability (compare bar 2 to bar 1). However, hptprβ-knockdown SN4741 cells displayed enhanced viability, even in the
absence of a stimulus (Figure 5C, bars 3 and 4). Taken together, those findings suggest that tyrosine phosphatase PTPRβ mediate RasGTPase/Erk activation and control cell viability in a P2X7 receptor-dependent manner.

3. Discussion

Our study reveals the purinergic P2X7 receptor modulates positively neuronal cell survival via Calcium-Calmodulin pathway regulation of the RasGRF1-mediated Ras GTPase/Erk1/2 activation and negatively via the tyrosine phosphatase, hPTPβ.

Purinergic signaling has been pointed out as the mediating mechanism for dopaminergic neuronal death [30] and may constitute an initial event in the development of Parkinson’s disease (PD). Several other studies have reported that the viability of the SN4741 cell line decreased dramatically after stimulation of purinergic receptors with 3 mM ATP for 20 min [30,37–39]. However, our results show that reducing the ATP concentration to 0.5 mM, six times lower than reported, not only preserves cell viability, but this concentration also effectively activates Ras and Erk1/2.

Considering that ATP and BZATP stimulation may activate several different purinergic receptors, such as P2X1, P2X3, P2X4, P2X7, and P2X2, and our pharmacological approach, using the P2X7 receptor-specific antagonist (A740003), ruled out this receptor as the sole activator of Erk1/2. Although it is not the only receptor, it is one of the major mediators of Ras activation. According to the results obtained, we postulated that ATP binds to the P2X7 and other P2X receptors. So, ATP binding to the P2X7 receptor mainly activates the Ras GTPase. Likewise, Ras activation is not affected by the presence of a specific antagonist (A740003) interfering with the binding capacity of the ligand to the P2X7 receptor. In contrast, Erk1/2 activation is partially affected, which is consistent with the fact that Erk1/2 can also be activated by Rap1/Raf pathway [40], Rho/Rho kinase (Rock) [41], and PKCs [42], different subtypes of G-protein alpha subunits, such as Gα12, Gα13, Gαq, and Gαi/o, or by beta-arrestin [43], in a Ras GTPases independent manner.

Ionotropic purinergic receptors, including the P2X7 receptor, modulate calcium fluxes that are key in neuronal physiology. Regarding Ras GTPase activation in neurons, there are two families of Ras GEFs that are associated with calcium fluxes: RasGRP and RasGRF. RasGRP has two EF domains that could bind calcium; however, the participation of Ca2+ as a RasGRP regulator has not been clearly demonstrated. The EF domains of this GEF do not seem to act as a typical calcium sensor. It is thought that they could play a role in the association of proteins to the plasma membrane [44]. Although Ras GRF1 activity does not depend on calcium movements directly, it depends on calmodulin. This has been demonstrated in a very elegant paper by Farnsworth et al. using Hek cells that do not express Ras GRF1 [36]. Our results are in complete agreement with those of Farnsworth et al., in which they also pointed out the calcium-calmodulin-mediated Ras activation via RasGRF1.

The Ras/MAPK signaling cascade may be considered a pathway that favors cell survival [45], although it has also been suggested that it can promote cell death [31,46,47]. Several models of neuronal toxicity associated with Parkinson’s disease show greater Erk1/2 activity present mainly in the cytoplasm and mitochondria accompanied by an increase in mitophagy [48–50]. While low levels of mitophagy confer neuroprotection, excessive activity due to increased phosphorylation of ERK is detrimental to the functionality of neurons.

The P2X7 purinergic receptor interacts with at least 11 proteins, including tyrosine phosphatase PTPRβ, a phosphatase whose expression is restricted to the central nervous system. The regulatory activity of this phosphatase on the anaplastic lymphoma protein kinase ALK has also been shown [51–54]. It should be noted that ALK activation has been associated with neuronal differentiation and neurite growth mediated by the MAPK pathway [55–58]. We observed that tyrosine phosphatases participate in the circuitry controlling Ras activation in SN4741 cells. This tyrosine phosphatase control of Ras activation coincides with that described by Kim et al., in which they reported that a basal phosphatase
activity dephosphorylated the P2X<sub>7</sub> receptor [16]. Our results suggest the participation of different phosphatases, where PTPRβ could display basal activity in neurons, while it would be a still unidentified phosphatase that increases its activity after purinergic stimulation. In this way, this increased phosphatase activity could act via the purinergic receptors themselves, as previously described [16], or via a receptor-independent mechanism, in any case, promoting Ras activation.

However, the regulation of Ras and Erk1/2 activity is not the only role of tyrosine phosphatases in dopaminergic neurons. These phosphatases activities promote other effects aiming at neuronal death. Our results show that the pharmacological inhibition of tyrosine phosphatases prevents ATP-stimulated death of dopaminergic neurons. This neuronal death protective effect via the inhibition of tyrosine phosphatases has already been described in the 6-OHDA-induced PD model [59], which pointed out these phosphatases as potential therapeutic targets. We focused on the role of PTPRβ tyrosine phosphatase, which, without being the only one involved in neuronal cell death when knocked-down, a blockage of SN4741 cell death was observed again.

In conclusion, as shown in Figure 6, our findings reveal the mechanism through which P2X<sub>7</sub> receptor stimulates Ras/Erk1/2 activation in SN4741 cells. Besides, we identified RasGRF1 as the GEF that specifically activates Ras, as well as the molecular mechanism of RasGRF1 activation of the P2X<sub>7</sub>/Ras pathway. Regulation of this novel signaling cascade requires the hPTPβ tyrosine phosphatase participation in the SN4741 dopaminergic neuronal cell viability. Therefore, we postulate that neuronal cell survival could be promoted by targeting hPTPβ. Future studies on this cellular context will help us clarify these cellular survival mechanisms and also find new therapeutic targets to prevent the death of dopaminergic neurons in Parkinson’s disease.

![Figure 6](image-url)

**Figure 6.** Low ATP concentrations promote cell survival via the CamKII/RasGRF1/RasGTPase/Erk pathway via the P2X<sub>7</sub>/hPTPB receptor system in SN4741 dopaminergic neurons. Scheme of the signaling cascade promoted by ATP stimulation of CamKII/RasGRF1/RasGTPase/Erk via the P2X<sub>7</sub> receptor that promotes cell survival in SN4741 dopaminergic neurons. Low concentrations of extracellular ATP activate the P2X<sub>7</sub> receptor. In a basal state of activation, the P2X<sub>7</sub> receptor is phosphorylated. Due to the action of hPTPB tyrosine phosphatase, the P2X<sub>7</sub> receptor is dephosphorylated, causing a greater flow of calcium, that promotes the activation of CamKII. Active CamKII binds to IQ domain of the RasGRF1 nucleotide exchanger. RasGRF1 promotes the change of RasGTPase from the inactive state (GDP-bound Ras) to the active state (GTP-bound Ras). Activated Ras can activate its main effector molecule Erk1/2. According to our results presented here, this described signaling cascade is involved in the cell survival of SN4741 dopaminergic neurons.
4. Experimental Procedures

4.1. Reagents

The following reagents were from Sigma-Aldrich (Lyon, France): DMSO, BzATP (2′(3′)-O-(4-Benzoylbenzoyl) adenosine 5′-triphosphate triethylammonium salt), A-740003 (N-1-[(cyanoimino) (5-quinolinylamino)methyl]amino)-2,2-dimethylpropyl)-2-(3,4dimethoxy phenyl)acetamide), GF109203X hydrochloride (3-[1-(Dimethylaminopropyl)indol-3-yl]-4-(indol-3-yl)maleimide hydrochloride, Bisindolylmaleimide I hydrochloride), sodium orthovanadate (Na$_3$VO$_4$), MISSION® esiRNA targeting EGFP (reference EHUEGFP) (EGFP was used as a negative transfection control because it was absent in our cellular system), and MISSION® esiRNA targeting human hPTPRβ (reference EHU158501).

Mouse monoclonal anti-RAS clone RAS10 antibody (Dil. 1:1000), anti-Cdc42 antibody (Dil. 1:1000), and anti-Rac clone23A8 (Dil. 1:1000) antibody were obtained from Millipore (Burlington, MA, USA). Anti-RAP1 sc:65 antibody (Dil. 1:1000) was obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA); rabbit monoclonal anti-Erk1/2 (Dil. 1:1000) and anti-phospho-Erk1/2 (Dil. 1:1000) were obtained from Cell Signaling Technology (Danvers, MA, USA). Monoclonal Anti-β-Actin antibody produced in mouse (Dil. 1:5000) were obtained from Cell Signaling Technology (Massachusetts, USA). The Clarity enhanced chemiluminescence (ECL) reagent was obtained from BioRad Laboratories Inc (Madrid, Spain).

4.2. Cell Culture and Transfections

SN4741 cells were cultured in DMEM (Dulbecco’s Modified Eagle Medium, Sigma-Aldrich), supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 100 units/mL of penicillin, and 100 ng/mL of streptomycin (Sigma-Aldrich) at 33°C in a 5% CO$_2$ atmosphere and a 95% relative humidity, as indicated by Son et al. [25]. For transfections, SN4741 cells were harvested at a rate of $8 \times 10^6$ cells/200 µL of complete medium previously chilled on ice. For each experimental point, 15 ng of esiRNA (MISSION® esiRNA, Sigma-Aldrich) were added to a previously cooled electroporation cuvette and then 200 µL of the cell suspension were added. Electroporation was performed in a Gene Pulser Xcell Electroporator (Bio-Rad) at 260 V and 950 µF [60]. Subsequently, transfected cells were brought into 10 mL of complete growth medium equilibrated at 33°C in a 100 mm diameter plate. After 24 h of incubation, the medium was changed, and cells were treated to continue the experiment.

Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS), 1% Penicillin/Streptomycin, and 1% Sodium pyruvate at 37°C in a 5% CO$_2$ atmosphere and a 95% relative humidity. A low passage number (0 to 20) of cell lines were maintained in 100-mm plates for adherent cells (Sarstedt, Nümbrecht, Germany). For plasmid and esiRNA transfections, HEK293 cells were seeded at 300,000 cells/well. The transfection was performed using XtremeGENE HD Roche (Paris, France) transfection reagent following manufacturer’s recommendations. To silence endogenous expression of human hPTPRβ to inhibit endogenous microRNA activity, cells were transfected with commercial esiRNAs following manufacturer’s recommendations. MISSION® esiRNA targeting EGFP (reference EHUEGFP) (EGFP was used as a negative transfection control because it was lacking in our cellular system) was used, as well as MISSION® esiRNA targeting human hPTPRβ (reference EHU158501).

4.3. Ras, Rap1, Rho, Rac1, and Cdc42 Activation Assay

Ras and Rap1 pull-down assay was performed using a GST fusion protein containing the RAP1-binding domain of Ral guanine nucleotide dissociation stimulator (GST-RalGDS) [61]. Rac1 pull-down assay was performed using a GST fusion protein containing the Rac1 binding domain of PAK1 (GST-RBD-PAK1) [62]. Cdc42 pull-down assay was performed using a GST fusion protein containing the Cdc42/Rac1 interactive binding domain of WASP (GST-CRIB-WASP) [63].
Cells were transfected with the indicated constructs or previously treated with specific inhibitors and, finally, lysed in 500 µL of lysis buffer (10 mM Tris, pH 7.6, 150 mM NaCl, 1% IGEPAL-360, 10 mM MgCl₂, 1 mM PMSF, 10 µg/mL aprotinin, 10 µg/mL leupeptin) [62]. Cell lysates were centrifuged at 13,500 rpm for 10 min at 4 °C, and 500 µg of protein (1 µg/µL) from the soluble fraction was incubated for 1 h at 4 °C with 50 µg of the GST-RBD-specific fusion protein. Precipitated proteins were eluted from beads using 2× loading buffer (12 mm Tris, pH 6.8, 5% glycerol, 0.4% SDS, 140 mm 2-mercaptoethanol, and 0.02% bromophenol blue), separated by SDS-PAGE, and analyzed by Western blotting with specific monoclonal antibodies. Immunoreactive bands were visualized using the ECL reagent. Band intensities were imaged using ChemiDoc MP Imaging System, and the images were analyzed with Image Lab 5.0. Software (Bio-Rad).

4.4. Cell Viability Assay

SN4741 cells were seeded in triplicate at 30 × 10³ cells/well in a 96-well plate. Then, cells were previously treated (+), or not (−), with A-740003, GF109203X hydrochloride, or sodium orthovanadate. The next day, cells were treated, which was stopped by removing the medium and washing cells with cold 1X PBS. One percent FBS medium was added to avoid cellular proliferation during the test. Cell viability was measured with CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT) following the manufacturer’s instructions (Promega, Madison, WI, USA): Briefly, 10 µL MTT reagent (MTT labeling reagent) was added to the fresh medium in each well. The plate was incubated at 33 °C in 5% CO₂ for 4 h, and the reaction was stopped by adding 100 µL of kit solubilization solution to each well overnight at 33 °C, and 5% CO₂. The absorbance was measured in a microplate reader (Synergy™ HT Multidetection Microplate Reader, BIORAD (Winooski, VT, USA)) at the wavelength of 570 nm. The values obtained were transformed into percentages, setting the value of 100% viability to the net absorbance of control cells. The rest of the values corresponding to different treatments are presented as percentages over the control.

To verify the MTT assay, we counted with a Neubauer counting chamber with cover glasses (dimensions are 24 mm L × 26 mm W × 0.4 mm H) (Blau brand). Cells were counted under the microscope. Sample preparation was done by an experienced senior laboratory personnel researcher. In order to reduce the errors caused by subjective central tendency. The samples were diluted with Trypan blue solution (Sigma-Aldrich) in a normal phosphate buffer saline at 1:5 ratio.

4.5. Statistical Analysis

All data are presented as mean ± S.E.M. Statistical analysis was performed using GraphPad Prism statistical software (version 5.0; GraphPad software (San Diego, CA, USA)). Comparisons between multiple experimental groups were made using one-way analysis of variance (ANOVA), followed by Bonferroni’s post hoc test. To determine the significance between data means, (* p < 0.05, ** p < 0.01, *** p < 0.001).

Author Contributions: Conceptualization, J.L.Z.; methodology, F.L.B., M.L.M., and A.A.S.; software, F.L.B.; validation, J.L.Z.; formal analysis, F.L.B. and J.L.Z.; investigation, F.L.B., M.L.M., A.A.S. and J.L.Z.; resources, J.L.Z.; data curation, F.L.B.; writing—original draft preparation, F.L.B., and J.L.Z.; writing—review and editing, H.M.L.; visualization, J.L.Z.; supervision, J.L.Z.; project administration, J.L.Z.; funding acquisition, J.L.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This work were supported by: A.A.S. is a recipient of a predoctoral Basque Government fellowship: PRE_2017_1_0016; M.L.M. is a recipient of a fellowship from Foundation “Jesús de Gangoiti y Barrera”; J.L.Z. was supported by the Instituto de Salud Carlos III (PI18/00207); J.L.Z. was supported by the Basque Government: (PIBA_2020_1_0048); J.L.Z. was supported by the University of Basque Country Grant: (US19/04). A.A.S. is a recipient of a predoctoral fellowship (PRE_2017_1_0016) from the Basque Government; M.L.M. is a recipient of a fellowship from Foundation “Jesús de Gangoiti y Barrera”; J.L.Z. was supported by the Instituto de
Salud Carlos III (PI18/00207), Basque Government (PIBA_2020_1_0048) and University of Basque Country Grant (US19/04).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The datasets generated during and analyzed during the current study are available from the corresponding author or principal investigator (last author) on reasonable request.

**Conflicts of Interest:** The authors have no relevant financial or non-financial interests to disclose. The authors declare that they have no conflict of interest with the contents of this article.

**Ethical Approval:** All authors qualify for authorship, approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Abbreviations**

ATP—Adenosine triphosphate; CaM—Ca2+/calmodulin (CaM)-dependent protein kinase II; CNS—Central nervous system; DA—Dopaminergic; DMSO—Dimethyl sulfoxide; Erk1/2—extracellular signal-regulated kinase 1/2; GAP—GTPase-activating proteins; GDI—Guanosine nucleotide dissociation inhibitor; GDP—guanosine diphosphate; GEF—Guanine nucleotide exchange factors; GST—Glutathione S-transferase; GTP—guanosine triphosphate; JNKs—Jun N-Terminal Kinase; MAPKs—Mitogen Activated Protein Kinases; Na3VO4—Sodium Orthovanadate; PAK1—PAK1 Serine/threonine-protein kinase 1; PD—Parkinson’s disease; Raf—Raf Serine/threonine-protein kinase; RasGRF1—Ras Protein Specific Guanine Nucleotide Releasing Factor 1; ROS—reactive oxygen species; PTPRβ—Protein Tyrosine Phosphatase Receptor β; SDS—Sodium dodecyl sulfate; SDS-PAGE—sodium dodecyl sulfate polyacrylamide gel electrophoresis; WASP—Wiskott–Aldrich Syndrome protein.

**References**

1. Draganov, D.; Lee, P.P. Purinergic Signaling Within the Tumor Microenvironment. *Adv. Exp. Med. Biol.* 2021, 1270, 73–87.

2. Markwardt, F. Human P2X7 receptors—Properties of single ATP-gated ion channels. *Biochem. Pharmacol.* 2020, 114307. [CrossRef] [PubMed]

3. Feng, W.; Wang, L.; Zheng, G. Expression and function of P2 receptors in hematopoietic stem and progenitor cells. *Stem Cell Investig.* 2015, 2, 14. [PubMed]

4. Agostinho, P.; Madeira, D.; Dias, L.; Simões, A.P.; Cunha, R.A.; Canas, P.M. Purinergic signaling orchestrating neuron-glia communication. *Pharmacol. Res.* 2020, 162, 105253. [CrossRef] [PubMed]

5. Andrejew, R.; Oliveira-Giacomelli, Á.; Ribeiro, D.E.; Glaser, T.; Andrade, G. The P2X7 Receptor: Central Hub of Brain Diseases. *Front. Mol. Neurosci.* 2020, 13, 124. [CrossRef] [PubMed]

6. Illes, P. P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases. *Int. J. Mol. Sci.* 2020, 21, 5996. [CrossRef]

7. Crabbé, M.; Van der Perren, A.; Bollaerts, I.; Kounelis, S.; Baekelandt, V.; Casteels, C.; Moons, L.; Van Laere, K. Increased P2X7 Receptor Binding is Associated with Neuroinflammation in Acute but Not Chronic Rodent Models for Parkinson’s Disease. *Front. Neurosci.* 2019, 13, 799. [CrossRef]

8. Wang, X.H.; Xie, X.; Luo, X.G.; Shang, H.; He, Z.Y. Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson’s disease. *Mol. Med. Rep.* 2017, 15, 768–776. [CrossRef] [PubMed]

9. Calzaferri, F.; Ruiz-Ruiz, C.; De Diego, A.M.G.; De Pascual, R.; Méndez-López, I.; Cano-Abad, M.F.; Maneu, V.; Ríos, C.D.L.; Gandía, L.; García, A.G. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases. *Med. Res. Rev.* 2020, 40, 2427–2465. [CrossRef]

10. Monif, M.; Burnstock, G.; Williams, D.A. Microglia: Proliferation and activation driven by the P2X7 receptor. *Int. J. Biochem. Cell Biol.* 2010, 42, 1753–1756. [CrossRef]

11. Skaper, S.D.; Facci, L.; Culbert, A.A.; Evans, N.A.; Chessell, I.; Davis, J.B.; Richardson, J.C. P2X(7) receptors on microglial cells mediate injury to cortical neurons in vitro. *Glia* 2006, 54, 234–242. [CrossRef] [PubMed]

12. Carmo, M.; Menezes, A.P.F.; Nunes, A.C.L.; Plüssova, A.; Rolo, A.; Palmeira, C.; Cunha, R.A.; Canas, P.; Andrade, G. The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis. *Neuropsychopharmacology* 2014, 81, 142–152. [CrossRef] [PubMed]

13. Dutta, G.; Zhang, P.; Liu, B. The lipopolysaccharide Parkinson’s disease animal model: Mechanistic studies and drug discovery. *Fundam. Clin. Pharmacol.* 2008, 22, 453–464. [CrossRef]
14. Oliveira-Giacomelli, Æ.; Albino, C.M.; de Souza, H.D.N.; Corrêa-Veloso, J.; Santos, A.P.D.J.; Baranová, J.; Ulrich, H. P2Y6 and P2X7 Receptor Antagonism Exerts Neuroprotective/Neuroregenerative Effects in an Animal Model of Parkinson’s Disease. Front. Cell Neurosci. 2019, 13, 476. [CrossRef] [PubMed]

15. Tufekci, K.U.; Genc, S.; Genc, K. The endotoxin-induced neuroinflammation model of Parkinson’s disease. Parkinsons Dis. 2011, 2011, 487450. [PubMed]

16. Kim, M.; Jiang, L.-H.; Wilson, H.; North, R.; Surprenant, A. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J. 2001, 20, 6347–6358. [CrossRef] [PubMed]

17. Adamsky, K.; Schilling, J.; Garwood, J.; Faissner, A.; Peles, E. Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin C. Oncogene 2001, 20, 609–618. [CrossRef]

18. Lenertz, L.Y.; Gavalta, M.L.; Zhu, Y.; Bertics, P.J. Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions. Immunol. Res. 2011, 50, 22–38. [CrossRef] [PubMed]

19. Qu, L.; Pan, C.; He, S.-M.; Lang, B.; Gao, G.-D.; Wang, X.-L.; Wang, Y. The Ras Superfamily of Small GTPases in Non-neoplastic Cerebral Diseases. Front. Mol. Neurosci. 2019, 12, 121. [CrossRef] [PubMed]

20. Sastre, A.A.; Montoro, M.L.; Gálvez-Martín, P.; Lacerda, H.; Lucía, A.; Llávero, F.; Zugaza, J. Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases. Int. J. Mol. Sci. 2020, 21, 6312. [CrossRef] [PubMed]

21. Nakhaeirad, S.; Haghighi, F.; Nouri, P.; Adariani, S.R.; Lissy, J.; Jasemi, N.S.K.; Dvorsky, R.; Ahmadian, M.R. Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms. Crit. Rev. Biochem. Mol. Biol. 2018, 53, 130–156. [CrossRef] [PubMed]

22. Chakrabarty, K.; Serchov, T.; Mann, S.A.; Dietzel, I.D.; Heumann, R. Enhancement of dopaminergic properties and protection mediated by neuronal activation of Ras in mouse ventral mesencephalic neurones. Eur. J. Neurosci. 2007, 25, 1971–1981. [CrossRef] [PubMed]

23. Heumann, R.; Moratalla, R.; Herrero, M.T.; Chakrabarty, K.; Drucker-Colin, R.; Garcia-Montes, J.R.; Simola, N.; Morelli, M. Dyskinesia in Parkinson’s disease: Mechanisms and current non-pharmacological interventions. J. Neurochem. 2014, 130, 472–489. [CrossRef] [PubMed]

24. Bourne, H.R.; Sanders, D.A.; McCormick, F. The GTPase superfamily: Conserved structure and molecular mechanism. Nature 1991, 349, 117–127. [CrossRef]

25. Son, J.H.; Chun, H.S.; Joh, T.H.; Cho, S.; Conti, B.; Lee, J.W. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J. Neurosci. 1999, 19, 10–20. [CrossRef] [PubMed]

26. Ferrari, D.; Los, M.; Bauer, M.K.; Vandenabeele, P.; Wesselborg, S.; Schulze-Osthoff, K. P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett. 1999, 447, 71–75. [CrossRef] [PubMed]

27. Inoue, K. Microglial activation by purines and pyrimidines. Glia 2002, 40, 156–163. [CrossRef] [PubMed]

28. Le Feuvre, R.; Brough, D.; Rothwell, N. Extracellular ATP and P2X7 receptors in neurodegeneration. Eur. J. Pharmacol. 2002, 447, 261–269. [CrossRef]

29. Le Stunff, H.; Auger, R.; Kanellopoulos, J.; Raymond, C. The Pro-451 to Leu polymorphism within the C-terminal tail of the human P2X7 receptor impairs cell death but not phospholipase D activation in murine thymocytes. Exp. Cell Res. 2001, 261–269. [CrossRef] [PubMed]

30. Jun, D.-J.; Kim, J.; Jung, S.-Y.; Song, R.; Noh, J.-H.; Park, Y.; Ryu, S.H.; Kim, J.-H.; Kong, Y.-Y.; Chung, J.-M.; et al. Extracellular ATP mediates necrotic cell swelling in SN4741 dopaminergic neurons through P2X7 receptors. J. Biol. Chem. 2007, 282, 37350–37358. [CrossRef]

31. Chu, C.; Alapat, D.; Wen, X.; Timo, K.; Burststein, D.; Lisanti, M.; Shears, S.; Kohtz, D.S. Ectopic expression of murine diphospho-inositol polyphosphate phosphohydrolase 1 attenuates signaling through the ERK1/2 pathway. Cell Signal. 2004, 16, 1045–1059. [CrossRef] [PubMed]

32. North, R.A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82, 1013–1067. [CrossRef] [PubMed]

33. Donnelly-Roberts, D.L.; Jarvis, M.F. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br. J. Pharmacol. 2007, 151, 571–579. [CrossRef] [PubMed]

34. Sturani, E.; Abbondio, A.; Branduardi, P.; Ferrari, C.; Zippel, R.; Martegani, E.; Vanoni, M.E.; Denis-Donini, S. The Ras Superfamily of Small GTPases Switch on/off Signaling Pathways in Neurodegenerative Diseases. Crit. Rev. Biochem. Mol. Biol. 2018, 53, 130–156. [CrossRef] [PubMed]

35. Amoroso, F.S.; Falzoni, S.; Adinolfi, E.; Ferrari, D.; Di Virgilio, F. The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis. 2012, 3, e370. [CrossRef] [PubMed]

36. Farnsworth, C.L.; Freshney, N.W.; Rosen, L.B.; Ghosh, A.; Greenberg, M.E.; Feig, L.A. Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. Nature 1995, 376, 524–527. [CrossRef] [PubMed]

37. Liu, Y.-W.; Chen, X.-Q.; Tian, X.; Chen, L.; Wu, Y.-X.; Huang, D.; Yi, H.-L.; Yi, C.-L.; Li, C.-Y. P2X3, but not P2X1, receptors mediate ATP-activated current in neurons innervating tooth-pulp. J. Huazhong Univ. Sci. Technol. Med. Sci. 2013, 33, 423–426. [CrossRef] [PubMed]

38. Prasad, P.; Stefos, G.C.; Becker, W. Extracellular ATP activates NFAT-dependent gene expression in neuronal PC12 cells via P2X receptors. BMC Neurosci. 2011, 12, 90. [CrossRef] [PubMed]

39. Sato, A.; Arimura, Y.; Manago, Y.; Nishikawa, K.; Aoki, K.; Wada, E.; Suzuki, Y.; Osaka, H.; Setsuie, R.; Sakurai, M.; et al. Parkin potentiates ATP-induced currents due to activation of P2X receptors in PC12 cells. J. Cell Physiol. 2006, 209, 172–182. [CrossRef] [PubMed]
40. Gündüz, D.; Troidl, C.; Tanislav, C.; Rohrbach, S.; Hamm, C.; Aslam, M. Role of PI3K/Akt and MEK/ERK Signalling in cAMP/Epac-Mediated Endothelial Barrier Stabilisation. *Front. Physiol.* 2019, 10, 1387. [CrossRef] [PubMed]

41. Birukova, A.A.; Smurova, K.; Birukov, K.G.; Kaibuchi, K.; Garcia, J.G.; Verin, A.D. Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction. *Microvasc. Res.* 2004, 67, 64–77. [CrossRef] [PubMed]

42. Minichiello, L. TrkB signalling pathways in LTP and learning. *Nat. Rev. Neurosci.* 2009, 10, 850–860. [CrossRef] [PubMed]

43. Belcheva, M.M.; Coscia, C.J. Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. *Neurosignals* 2002, 11, 34–44. [CrossRef] [PubMed]

44. Stone, J.C. Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells. *Genes Cancer* 2011, 2, 320–334. [CrossRef]

45. Baines, C.P.; Zhang, J.; Wang, G.W.; Zheng, Y.T.; Xiu, J.X.; Cardwell, E.M.; Bolli, R.; Ping, P. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: Enhanced mitochondrial PKC epsilon-MAPK interactions and differential MAPK activation in PKC epsilon-induced cardioprotection. *Circ. Res.* 2002, 90, 390–397. [CrossRef]

46. Ren, Y.; Jiang, H.; Yang, F.; Nakaso, K.; Feng, J. Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. *J. Biol. Chem.* 2009, 284, 4009–4017. [CrossRef]

47. Zhu, J.; Schnellmann, K.G. A death-promoting role for extracellular signal-regulated kinase. *J. Pharmacol. Exp. Ther.* 2006, 319, 991–997. [CrossRef] [PubMed]

48. Baines, C.P.; Zhang, J.; Wang, G.W.; Zheng, Y.T.; Xiu, J.X.; Cardwell, E.M.; Bolli, R.; Ping, P. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: Enhanced mitochondrial PKC epsilon-MAPK interactions and differential MAPK activation in PKC epsilon-induced cardioprotection. *Circ. Res.* 2002, 90, 390–397. [CrossRef]

49. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

50. Deuel, T.F. Anaplastic lymphoma kinase: “Ligand Independent Activation” mediated by the PTN/RPTPbeta/zeta signaling pathway: An alternative mechanism of receptor tyrosine kinase activation. *Biochim. Biophys. Acta* 2013, 1834, 2219–2223. [CrossRef]

51. Baines, C.P.; Zhang, J.; Wang, G.W.; Zheng, Y.T.; Xiu, J.X.; Cardwell, E.M.; Bolli, R.; Ping, P. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: Enhanced mitochondrial PKC epsilon-MAPK interactions and differential MAPK activation in PKC epsilon-induced cardioprotection. *Circ. Res.* 2002, 90, 390–397. [CrossRef]

52. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

53. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

54. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

55. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

56. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

57. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

58. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

59. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

60. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

61. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

62. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]

63. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? *Cell Signal.* 2007, 19, 2434–2443. [CrossRef]